利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

40 条记录 (耗时 0.04 秒)

    Triazolopyrimidine cannabinoid receptor 1 antagonists
    5.
    发明授权
    Triazolopyrimidine cannabinoid receptor 1 antagonists 有权
    三唑并嘧啶大麻素受体1拮抗剂

    公开(公告)号：US07452892B2

    公开(公告)日：2008-11-18

    申请号：US11455083

    申请日：2006-06-16

    申请人： Gang Wu ,  Amarendra B. Mikkilineni ,  Philip M. Sher ,  Natesan Murugesan ,  Zhengxiang Gu

    发明人： Gang Wu ,  Amarendra B. Mikkilineni ,  Philip M. Sher ,  Natesan Murugesan ,  Zhengxiang Gu

    IPC分类号： A61K31/519 ,  A01N43/90 ,  C07D487/00

    CPC分类号： C07D487/04

    摘要： The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.

    摘要翻译： 本申请描述了根据式I和II的化合物，包含至少一种式I或II的化合物和任选的一种或多种另外的治疗剂的药物组合物和使用根据式I和II的化合物的治疗方法 单独并与一种或多种另外的治疗剂组合。 该化合物具有以下通式：包括所有前药，溶剂化物，药学上可接受的盐和立体异构体，其中R 1，R 2，R 3， 本文描述了R 4和R 5。

    O-aryl glucoside SGLT2 inhibitors and method
    9.
    发明授权
    O-aryl glucoside SGLT2 inhibitors and method 有权
    O-芳基葡糖苷SGLT2抑制剂及方法

    公开(公告)号：US06683056B2

    公开(公告)日：2004-01-27

    申请号：US09791512

    申请日：2001-02-23

    申请人： William N. Washburn ,  Philip M. Sher ,  Gang Wu

    发明人： William N. Washburn ,  Philip M. Sher ,  Gang Wu

    IPC分类号： A61K3170

    CPC分类号： C07H15/203 ,  C40B40/00

    摘要： wherein when Y is  or heteroaryl; A is —O(CH2)m, S, —NH(CH2)m, or (CH2)n where n is 0-3 and m is 0-2; and R1 to R6 are as defined herein. A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with one, two or more other antidiabetic agents, and/or one, two or more hypolipidemic agents.

    摘要翻译： 其中当Y是 - 杂芳基时，A是-O（CH2）m，S，-NH（CH2）m或（CH2）n，其中n是0-3，m是0-2; R 1至R 6 本发明还提供了一种用于治疗糖尿病和相关疾病的方法，其使用单独的SGLT2抑制量的上述化合物或与一种，两种或更多种其它抗糖尿病药物组合，和/或一种，两种或更多种降血脂剂 。

    2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
    10.
    发明授权
    2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors 有权
    2-氨基-3-官能化的四氢化萘衍生物和相关的糖原磷酸化酶抑制剂

    公开(公告)号：US07365061B2

    公开(公告)日：2008-04-29

    申请号：US11273167

    申请日：2005-11-14

    申请人： Philip M. Sher ,  Gang Wu ,  Wei Meng ,  Alexandra A. Nirschl ,  William N. Washburn ,  Terry Stouch

    发明人： Philip M. Sher ,  Gang Wu ,  Wei Meng ,  Alexandra A. Nirschl ,  William N. Washburn ,  Terry Stouch

    IPC分类号： A61K31/404 ,  A61K31/454 ,  A61K31/397 ,  C07D209/04 ,  C07D205/04 ,  C07D401/08

    CPC分类号： C07D209/42 ,  C07D235/24 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D491/04 ,  C07D493/08 ,  C07D495/04

    摘要： Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer. These novel compounds have the structure or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, R1, R2, X, Y and Z are defined herein.

    摘要翻译： 提供了新型化合物，其是可用于治疗，预防或减缓需要糖原磷酸化酶抑制剂治疗（如糖尿病和相关病症（如高血糖，葡萄糖耐量异常，胰岛素抵抗和高胰岛素血症））的疾病进展的糖原磷酸化酶抑制剂，微血管 与糖尿病相关的并发症（如视网膜病变，神经病变，肾病和延迟伤口愈合），与糖尿病相关的大血管并发症（心血管疾病如动脉粥样硬化，心脏功能异常，心肌缺血和中风）以及代谢综合征及其组成条件 包括高血压，肥胖和血脂异常（包括高甘油三酯血症，高胆固醇血症和低HDL）以及其他疾病如非心脏缺血，感染和癌症。 这些新化合物具有其结构或立体异构体或前药或其药学上可接受的盐，其中W，R 1，R 2，X，Y和Z在本文中定义。